United States v. Blattner

195 F. Supp. 3d 1205, 2016 U.S. Dist. LEXIS 114225, 2016 WL 4491509
CourtDistrict Court, D. New Mexico
DecidedJuly 19, 2016
DocketNo. CR 13-0328 JB
StatusPublished
Cited by1 cases

This text of 195 F. Supp. 3d 1205 (United States v. Blattner) is published on Counsel Stack Legal Research, covering District Court, D. New Mexico primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Blattner, 195 F. Supp. 3d 1205, 2016 U.S. Dist. LEXIS 114225, 2016 WL 4491509 (D.N.M. 2016).

Opinion

MEMORANDUM OPINION AND ORDER

James 0. Browning, UNITED STATES DISTRICT JUDGE

THIS MATTER comes before the Court on the Defendant’s Motion to Withdraw Guilty Plea, filed October 29, 2015 (Doc. 148)(“Motion”). The Court held hearings on the Motion on November 10, 2015, November 23, 2015, December 2, 2015, and December 9, 2015. The primary issue is whether Defendant Chris Blattner has given the Court a fair and just reason to allow him to withdraw his guilty plea, by asserting that he took Lysergic Acid Diethyla-mide (“LSD”) the evening before his plea colloquy with the Honorable Karen B. Molzen, Chief United States Magistrate Judge. The Court has weighed the seven factors that the United States Court of Appeals for the Tenth Circuit requires it to consider when determining whether to allow a defendant to withdraw a guilty plea, and it determines that Blattner has not given the Court a fair and just reason for permitting him to withdraw his plea. The Court, therefore, denies the Motion.

[1207]*1207FINDINGS OF FACT

Rule 12(d) of the Federal Rules of Criminal Procedure requires the Court to state its essential findings on the record when deciding a motion that involves factual issues. See Fed. R. Crim. P. 12(d) (“When factual issues are involved in deciding a [pretrial] motion, the court must state its essential findings on the record.”).1 The findings of fact in the Memorandum Opinion and Order shall serve as the Court’s essential findings for purposes of. rule 12(d).

1. LSD’s Pharmacological Effects.

1. LSD2 has been in usage in the United States of America since the 1960s. See [1208]*1208Transcript of Hearing at 72:17-73:11 (Tor-rez, Tella)(taken November 23, 2015), filed December 4, 2015 (Doc. 165)(“Nov. 23 Tr”).

2. LSD is used mostly by teenagers and young adults no older than their 20s, although occasionally there are instances of older people using it. See Transcript of Hearing at 24:10-26:5 (taken December 2, 2015), filed December 8, 2015 (Doc. 172)(Court, Goldberg, Kochersberger, Tor-rez)(“Dec. 2 Tr.”).

3. Today, LSD is used far less than in decades past, particularly in New Mexico. See Dec. 2 Tr. at 26:6-15 (Goldberg, Tor-rez).

4. Although the exact mechanism is not completely understood, LSD seems to affect some of the deepest and more central parts of the primitive brain in the areas where it is believed that emotion, feelings, and perception are mediated3—the Hippo-campus4 and the Cingulate Gyrus.5 See Dec. 2 Tr. at 27:19-28:3 (Goldberg).

5. The nature and duration of the effects of LSD may vary depending on factors such as the product’s quality, the dose ingested, and the individual user’s experience, personality, and metabolism. See Nov. 23 Tr. at 85:24-86:13 (Telia); Dec. 2 Tr. at 28:4-13 (Goldberg).

6. Whether a person might exhibit any observable symptoms after ingesting LSD depends on several factors, including his or her personality, expectations, dosage, and tolerance. See Nov. 23 Tr. at 78:10-19 (Tel-ia).

7. LSD produces physiological effects on the brain and body, as well as psychological effects. See Nov. 23 Tr. at 75:5-7 (Tel-ia); Dec. 2 Tr. at 28:6:30:14 (Goldberg).

8. LSD’s physiological effects can include dilated pupils, increased blood pressure and heart rate, increased body temperature, salivation, lacrimation,6 sweating, nausea, tremor, and hyperreflexia—which is enhanced reflexes of the muscular flex-ors—dizziness, piloerection,7 hypoglycemia, feelings of numbness, muscle weakness, and sleeplessness or “wakefulness.” Nov. 23 Tr. at 75:22-76:9 (Telia); Dec. 2 Tr. at 28:14-20 (Goldberg).

9. LSD’s physiological effects are not always manifested in those who have ingested the drug, and they are the same as, or very similar to, the physiological signs of anxiety. See Dec. 2 Tr. at 30:15-31:11 (Goldberg, Kochersberger).

10. For example, any person who is placed in a circumstance that makes them uncomfortable could experience dilated pupils, increased heart rate, sweating, and [1209]*1209tremors. See Dec. 2 Tr. at 30:25-31:3 (Goldberg).

11. A person coming into contact with an individual under LSD’s influence would not normally observe most of LSD’s physiological symptoms—such as dilated pupils, elevated blood pressure, and dizziness—in the absence of in-depth conversation, or mood and emotional changes. See Nov. 23 Tr. at 81:9-82:25 (Kochersberger, Telia); Dec. 2 Tr. at 31:4-32:4 (Goldberg, Kochersber-ger).

12. Many of LSD’s physiological symptoms, such as dizziness, nausea, and muscle weakness, would generally be undetectable unless they were either very extreme, or the user informed someone that he or she was experiencing those symptoms. See Dec. 2 Tr. at 45:18-46:6 (Goldberg).

13. LSD also has psychological effects, including affectation of a person’s perception, mood, emotion, intellectual process, and thoughts. See Nov. 23 Tr. at 74:21-24 (Telia).

14. Psychologically, LSD can produce anxiety, altered thinking, altered time perception, convoluted and mixed sensory experiences—such as hearing colors or seeing sounds—visual hallucinations, a sense of enhanced spirituality and spiritual experiences, loss of self, a merging of the individual with the environment around the user, and a loss of boundaries in terms of where the user ends and the world around the user begins. See Dec. 2 Tr. at 28:20-29:11 (Goldberg).

15. LSD may cause marked effects on mood and emotions, including sudden or inappropriate laughing or crying without any or only a slight provocation, euphoria and dysphoria. See Nov. 23 Tr. at 76:14-18 (Telia); id. at 83:9-86:3 (Kochersberger, Telia); Dec. 2 Tr. at 32:10-17 (Goldberg).

16. Even very perceptive observers may not know that someone, particularly a seasoned drug user, is under LSD’s influence. See Dec. 2 Tr. at 31:24-32:4 (Goldberg, Kochersberger); id at 45:3-17 (Goldberg, Torrez).

17. Individuals under LSD’s influence are focused on their own internal emotional experiences, are not focused on whatever is going on around them, and tend to say whatever they need to say to get out of the situation in which they are present in order to focus on their LSD experience. See Dec. 2 Tr, at 35:7-21 (Goldberg).

18. An LSD “trip” begins approximately thirty minutes after the drug is ingested, peaks in about four hours and it has a four-hour half-life, meaning that twelve hours after ingesting the drug, a person is down to about an eighth of the initial dose. Dec. 2 Tr. at 29:12-25 (Goldberg). See Nov. 23 Tr. at 77:17-22 (Telia).

2. Blattner’s Pre-Trial Criminal Histo-a

19. Blattner has been convicted of various felonies, misdemeanors, and juvenile offenses. See Nov. 23 Tr. at 26:13-21 (Blattner, Torrez).

20. Blattner was convicted of trafficking in a controlled substance in 2000 in Bernal-illo County, New Mexico. See Nov. 23 Tr. at 26:13-21 (Blattner, Torrez).

21.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Baca v. United States
D. New Mexico, 2023

Cite This Page — Counsel Stack

Bluebook (online)
195 F. Supp. 3d 1205, 2016 U.S. Dist. LEXIS 114225, 2016 WL 4491509, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-blattner-nmd-2016.